-
1 month ago | 
oncpracticemanagement.com | Patricia A. Stewart |Phoebe Starr |Wayne Kuznar |Cecile Miller
The landscape of cancer and immunology has gone through major scientific advances in research over the past 2 decades. The emergence of immunotherapy as a treatment option for patients diagnosed with cancer has led to improvements in patient outcomes. Patients diagnosed with certain forms of cancer can now live longer and enjoy good quality of life.
-
Jan 15, 2025 | 
oncpracticemanagement.com | Wayne Kuznar |Patricia A. Stewart
Subgroup analyses presented at the American Society of Hematology (ASH) Annual Meeting San Diego support the clinical benefit of brentuximab vedotin (Adcetris; Pfizer) in heavily pretreated patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
-
May 28, 2024 | 
theoncologypharmacist.com | William King |Patricia Stewart |Charlie Dawson |Wayne Kuznar
Get TOP in Your Inbox!
Stay up to date with the latest oncology pharmacy news and insights by subscribing to our eNewsletter.
-
May 23, 2024 | 
theoncologynurse.com | Wayne Kuznar
San Antonio—A 9-month twice weekly structured exercise program improved measures of fatigue and quality of life among patients with metastatic breast cancer, according to a randomized controlled trial presented by Anne M. May, PhD, professor, Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, The Netherlands, at the 2023 San Antonio Breast Cancer Symposium.
-
Apr 11, 2024 | 
theoncologynurse.com | Wayne Kuznar
San Diego—Patients with relapsed or refractory acute leukemia with rearrangement in the KMT2Ar gene, an aggressive and difficult-to-treat leukemia, had an overall response rate of 63% when treated with the investigational agent revumenib, according to data from the single-arm pivotal phase 2 AUGMENT-101 study presented by Ibrahim Aldoss, MD, associate professor, Department of Hematology and Stem Cell Transplant, City of Hope National Medical Center, Duarte, California, at the 65th American...
-
Feb 28, 2024 | 
oncpracticemanagement.com | Wayne Kuznar |Phoebe Starr
The overwhelming majority of postmenopausal patients aged 50 to 69 years with favorable-risk stage I hormone receptor–positive (HR+) breast cancer who opted out of radiation therapy were disease-free 5 years after surgery, according to results of the IDEA trial.
-
Feb 5, 2024 | 
theoncologynurse.com | Wayne Kuznar
San Antonio—A 9-month twice weekly structured exercise program improved measures of fatigue and quality of life among patients with metastatic breast cancer, according to a randomized controlled trial presented by Anne M. May, PhD, professor, Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, The Netherlands, at the 2023 San Antonio Breast Cancer Symposium.
-
Feb 5, 2024 | 
theoncologynurse.com | Wayne Kuznar
San Antonio—Dual HER2-directed therapy with tucatinib and trastuzumab emtansine (T-DM1) extended progression-free survival (PFS) compared with T-DM1 alone in patients with previously treated, resectable, locally advanced or metastatic HER2-positive breast cancer.
In the HER2CLIMB-02 study, the tucatinib and T-DM1 doublet improved median PFS to 9.5 months from 7.4 months with T-DM1 monotherapy, corresponding to a 24% improvement in median PFS (hazard ratio, 0.76; P=.0163), said Sara A.
-
Jan 22, 2024 | 
oncpracticemanagement.com | Wayne Kuznar |Phoebe Starr
San Antonio—A 9-month twice weekly structured exercise program improved measures of fatigue and quality of life among patients with metastatic breast cancer, according to a randomized controlled trial presented by Anne M. May, PhD, professor, Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, The Netherlands, at the 2023 San Antonio Breast Cancer Symposium.
-
Dec 11, 2023 | 
networthynews.com | Wayne Kuznar
SAN ANTONIO– The addition of inavolisib to palbociclib (Ibrance) plus fulvestrant (Faslodex) enhanced progression-free survival (PFS) in clients with reoccurring PIK3CA-altered HR-positive, HER2-negative innovative breast cancer, according to the INAVO120 trial.
